# PAN-Biotech GmbH

> PAN-Biotech GmbH, founded in 1988 in Aidenbach, Germany, manufactures cell culture media, sera, buffers, reagents, water and GMP-grade downstream processing consumables — from RUO (research-use-only) to GMP — for cell & gene therapy, mRNA, vaccine and antibody manufacturing. PAN-Celltech GmbH is its dedicated GMP arm and manufacturer of record; GMP products are manufactured in an EU Annex 1 facility within an ISO 9001 quality system (EU Annex 1 is a demonstrated, audit-proven capability, not a certification). Beyond standard compendial (Ph. Eur./USP) quality, PAN-Biotech manufactures "Beyond Compendial" products — including WFI Beyond water and beyond-compendial buffers and reagents — engineered to ICH-level impurity control (elemental impurities, residual solvents, nitrosamines, extractables/leachables, endotoxins, nucleases). Its flagship publication series, the In-Depth Industry Editions, sets these standards out in full: D01 Downstream, D02 Water (The WFI Beyond Standard) and A02 Monoclonal antibodies.

This file indexes PAN-Biotech's key website content for AI assistants and answer engines. Individual product SKU pages (hundreds of media/buffer/reagent variants) are omitted here for signal — see the Products section for catalog entry points, or the full sitemap for exhaustive listings.

Content numbering used across the site: In-Depth Industry Editions are numbered by area (D = Downstream, A = Applications: D01, D02, A02); technical papers are TP-01 to TP-04; customer case studies are CS-01 to CS-06.

## In-Depth Industry Editions (flagship series)

Long-form, numbered technical briefings by PAN-Biotech / PAN-Celltech, authored by CEO Jens Hartmann. Each edition takes one bioprocess topic and sets a written, measurable standard for it, proven on the Certificate of Analysis. Editions are free, ungated HTML pages with an optional PDF. Where a technical paper makes a single argument, an edition sets a standard in depth. All three editions are live.

- [In-Depth Industry Editions — series index](https://pan-biotech.com/in-depth-industry-editions/): Overview of all editions (D01 Downstream, D02 Water, A02 Monoclonal antibodies).

### [Edition D01 — Downstream: Standardising the Downstream](https://pan-biotech.com/de-risking-biomanufacturing/)
One qualified GMP toolkit built from a small set of recurring stock solutions — research grade to GMP, with the process-specific tail covered by custom manufacture. PDF: https://pan-biotech.com/wp-content/uploads/PAN_InDepth_D01_Downstream_CD_Rev1.2.pdf

### [Edition D02 — Water: The WFI Beyond Standard](https://pan-biotech.com/the-wfi-beyond-standard/)
A defined, published, beyond-compendial standard for Water for Injection used as an excipient / for further manufacturing. PDF: https://pan-biotech.com/wp-content/uploads/PAN_InDepth_D02_Water_WFI_Beyond_Standard_Rev2.3.pdf
- Core argument: "meets WFI" is a floor, not a ceiling. The European WFI monograph traces back to the first Ph. Eur. (1969); two waters can both be legitimate WFI yet differ greatly on endotoxin, nucleases and trace metals. Water feeds nearly every buffer, medium and final formulation, so a deficiency cascades through the whole process and often surfaces late (silent stability loss, failed Phase 1-3 time-points).
- Specification vs. Ph. Eur. 0169 limit: conductivity ≤0.2 µS/cm vs. ≤1.1 µS/cm (>5x lower); total organic carbon ≤0.05 mg/L vs. ≤0.5 mg/L (10x lower); endotoxin <0.005 EU/mL vs. ≤0.25 EU/mL (>50x lower); RNase and DNase not detected; sterile; animal-component-free.
- Measured on a real production batch (Art. CT-981000, Lot 2560826): conductivity 0.128 µS/cm, TOC 0.011 mg/L (~45x below the limit), endotoxin <0.005 EU/mL, nucleases not detected, sterility no growth.
- Elemental impurities: the water monograph sets no elemental-impurity limits. The WFI Beyond Standard gives all 24 ICH Q3D elements a defined specification (launch criterion: 50% of the ICH Q3D parenteral limit) and reports measured ICP-MS values on every Certificate of Analysis. On the reference lot, 22 of 24 were below the limit of quantification; only antimony and chromium were detected, each far below its limit.
- Copper and iron — the two metals that catalyse antibody oxidation (Fenton chemistry) and drive aggregation — are both measured and reported (oxidation-metals addendum); both were below LOQ on the reference lot. Iron is required neither by the water monograph nor by ICH Q3D.
- Signed BSE/TSE & ICH Q3 declaration: non-animal origin (out of scope of EMA/410/01 Rev. 3); residual solvents (ICH Q3C), nitrosamines (EMA guidance) and elemental impurities (ICH Q3D) risk-assessed across product-contact materials.
- Manufacturing: EU GMP Annex 1 (GMP-compliant, audit-proven — Annex 1 is a capability, not a certification); 0.1 µm sterile filtration; aseptic fill into single-use containers gamma-irradiated to a validated 10⁻⁶ sterility assurance level; media fills twice a year; 2-year shelf life at +15 to +25 °C (ICH-format stability study).
- Regulatory: filed FDA Type IV (excipient) Drug Master File MF044505; companion DPBS Type IV (excipient) DMF MF044371; referenceable in IND/BLA via Letter of Authorization.
- Formats: 500 mL and 1000 mL bottles; single-use gamma-irradiated bags from 1 to 1000 L; custom fills from 1 mL on request. Article numbers CT-981500 to CT-981000B.
- One water standard, three grades: Sterile Water for Cell Culture (research, P-series), WFI Quality Water (GMP, CT-99xxxx) and WFI Beyond (GMP, beyond-compendial, CT-98xxxx) form a matched continuum — qualify once, scale without re-qualifying the water. WFI Beyond is opt-in.
- Modality relevance: mAbs (trace metals, ultra-low endotoxin), mRNA/LNP (nuclease-free), cell & gene therapy (endotoxin, nuclease-free, sterility), vaccines (endotoxin and sterility at scale), recombinant proteins (endotoxin, organic carbon).
- "Built on WFI Beyond" is the mark for a process whose water meets the standard — for developers, CDMOs and sponsors to reference in filings and diligence.
- Scope note: WFI Beyond is a raw material / excipient for compounding media, buffers and as a diluent for further manufacturing — not Sterile Water for Injection for direct human use.

### [Edition A02 — Monoclonal antibodies: Standardising the Antibody Program](https://pan-biotech.com/standardising-the-antibody-program/)
The 13-step monoclonal-antibody program — five upstream steps, seven downstream steps and a QC & stability step — delivered as ready-to-use process bundles, one labelled box per step; the water base is WFI Beyond (D02). PDF: https://pan-biotech.com/wp-content/uploads/PAN_InDepth_A02_Monoclonal-Antibodies_CD_Rev2.0.pdf

## Technical Papers (TP-01 to TP-04)

PAN-Biotech's core technical differentiation: a single quality specification for buffers, reagents and water that applies across the whole downstream process and across modalities (monoclonal antibodies, mRNA/LNP, cell & gene therapy, vaccines) — "qualify once, never switch supplier." The technical papers make the individual arguments; the In-Depth Industry Editions above set the full standards. All papers are free, ungated HTML pages with an optional PDF.

### [TP-01 — The Open Downstream](https://pan-biotech.com/the-open-downstream/)
Flagship technical paper on downstream processing economics and PAN-Biotech's GMP downstream system. Rev 1.6, October 2026, by CEO Jens Hartmann. PDF: https://pan-biotech.com/wp-content/uploads/tp_PAN-Biotech_The-Open-Downstream.pdf
- One coherent GMP-grade foundation of 32 on-stock products serving four applications; combined output up to ~1.8 million litres a year; Pharma Tech Outlook Top 10 CMOs in Europe (2024).
- Downstream processing accounts for roughly half (often more for antibodies) of a biologic's production cost and is where a single mistake is most expensive to unwind; one lost lot at commercial scale can erase years of unit-price savings.
- Failure points addressed: variable/off-spec raw materials, mid-programme supplier changes (re-validation, re-filing), in-house buffer inconsistency, failed lots at scale, documentation/DMF gaps, animal-origin questions, residual nucleases, trace-metal (copper/iron) oxidation.
- A qualified GMP product for every DSP step — capture, viral inactivation, chromatographic polishing, UF/DF, formulation — built on WFI-quality water; all standard RUO and GMP items in stock and dispatched worldwide in 1-2 days.
- Qualify once and scale without re-qualifying: 500 mL and 1000 mL bottles and single-use bags from 1 L to 1,000 L on request; research grade (P-) mirrored by GMP grade (CT-).
- Options at every step: standard GMP product, build-your-own (concentrates), WFI Beyond (opt-in quality ceiling), custom GMP formulation without switching supplier, DMF support, ICH-format stability studies.
- Audit-proven: audited successfully by NASDAQ- and DAX-listed pharma and small biotechs; remote or hybrid audits available.
- Track record: ~50,000 L of GMP supply delivered in under five weeks for a vaccine manufacturer; ~150,000 L (~300,000 bottles) over nearly two years with no rejections recorded.

### [TP-02 — Beyond Compendial, Applied to Buffers and Reagents](https://pan-biotech.com/beyond-compendial-applied-to-buffers-and-reagents/)
Extends the "beyond compendial" quality standard from water to GMP buffers and reagents. Rev 1.0, Aug 2026, PAN-Celltech R&D.
- Core argument: compendial (Ph. Eur./USP) buffers meet the monograph, but a modern regulatory filing is judged against the ICH impurity dossier, not the monograph alone.
- Five impurity classes addressed beyond the monograph: elemental impurities (ICH Q3D, 24 elements via ICP-MS — critical for mAb oxidation/aggregation risk); residual solvents (ICH Q3C); nitrosamines/mutagenic impurities (ICH M7(R2) and current EMA guidance — the class behind industry-wide recalls since 2018); extractables & leachables (ICH Q3E draft — DEHP, bisphenol A and dioxin tested negative); endotoxins & nucleases (below compendial limit, nuclease-free certified).
- Also covers animal-origin/TSE-BSE compliance (animal-component-free, EMA/410/01-aligned).
- Documentation is treated as a core product: raw measured values (not just pass/fail) are provided for ICH Q3D assessment on the Certificate of Analysis, with optional DMF listing and stability studies on request.
- One specification is positioned to cover all four modalities (mAbs, mRNA/LNP, cell & gene therapy, vaccines) as an integrated control system with lot-by-lot reporting, rather than a modular pick-list.

### [TP-03 — From Bench to GMP: Organizing and Scaling Your Buffer Supply](https://pan-biotech.com/from-bench-to-gmp-organizing-and-scaling-your-buffer-supply/)
Practical guide to the make-vs-buy decision for process buffers.
- The make-vs-buy inflection point typically hits at IND/IMPD filing or the first GMP manufacturing run, when buffer volumes move from litres to tens/hundreds of litres.
- Five hidden costs of staying in-house: QC/release testing per batch, documentation burden ("batch records are part of the product"), batch-to-batch consistency risk from manual variation (weighing, water quality, pH adjustment, filtration), supply security resting on one or two people, and the opportunity cost of scientist time spent on logistics instead of the molecule.
- Five-point readiness checklist: buffer volumes make manual prep a recurring problem; GMP use expected within 12-18 months; buffer QC competes with product-focused work; supply is vulnerable to key staff departures; scientist time is better spent on molecule development.
- What to demand from a GMP supply partner: Certificate of Analysis per batch, DMF regulatory support, stability data, raw-material traceability, audit-accessible quality systems, and pack sizes that scale from development through commercial production. The single most valuable supplier capability cited is the ability to customize your own formulation, so it can move into GMP production without switching suppliers.

### [TP-04 — WFI Beyond: Water for Injection Beyond the Monograph](https://pan-biotech.com/wfi-beyond-beyond-compendial/)
Technical paper introducing the WFI Beyond water standard. Rev 1.4, October 2026, by CEO Jens Hartmann. The complete, current specification is defined in Edition D02, The WFI Beyond Standard (see above). PDF: https://pan-biotech.com/wp-content/uploads/tp_PAN-Biotech_WFI-Beyond-1.pdf
- Core claim: "meets WFI" is a floor, not a ceiling — the European WFI standard dates to the first Ph. Eur. (1969), before modern biologics existed.
- Key attributes vs. compendial limit: endotoxin more than 50x lower; total organic carbon 10x lower by specification (typical result ~45x lower); conductivity more than 5x lower; RNase and DNase not detected; sterile, single-use.
- All 24 ICH Q3D elemental impurities measured by ICP-MS with actual values on every Certificate of Analysis; on a representative lot 22 of 24 were below LOQ. Copper and iron (the Fenton-chemistry oxidation pair) were both below LOQ and are reported in an oxidation-metals addendum; iron is required neither by the water monograph nor by ICH Q3D.
- Impurity dossier beyond the monograph: ICH Q3C residual solvents, nitrosamines per current EMA guidance, TSE/BSE safety (non-animal materials, out of scope of EMA/410/01 Rev. 3), backed by a signed declaration.
- Manufacturing: EU GMP Annex 1 within ISO 9001; 0.1 µm sterile filtration; aseptic fill into gamma-irradiated single-use containers (SAL 10⁻⁶, ISO 11137); media fills twice a year; 2-year shelf life (ICH-format stability study); container film screened negative for DEHP/phthalates, bisphenol A, dioxin and melamine.
- Regulatory: filed FDA Type IV (excipient) DMF MF044505 (DPBS Type IV DMF MF044371).
- Packs: CT-98 series — 500 mL and 1000 mL bottles (CT-981500, CT-981000), single-use bags 1-1000 L (CT-98001B to CT-981000B); on stock: bottles and 20 L bags.
- Modality relevance: mAbs, mRNA/LNP, cell & gene therapy, vaccines, recombinant proteins.

## Downstream & Water — product entry points

- [The Open Downstream — downstream hub](https://pan-biotech.com/downstream/): Overview of PAN-Biotech's GMP downstream system, with links to the technical papers and editions.
- [Downstream Products (DSP)](https://pan-biotech.com/products-downstream-dsp/): Product entry point for downstream processing consumables (buffers, stock solutions, reagents).
- [WFI Beyond](https://pan-biotech.com/wfi-beyond/): Product page for the beyond-compendial Water for Injection grade (CT-98 series).
- [WFI Quality Water](https://pan-biotech.com/wfi-quality-water/): GMP WFI-quality water (CT-99 series), the compendial water base of the standard range.
- [Water](https://pan-biotech.com/water/): Water portfolio — research-grade sterile water, GMP WFI Quality Water and WFI Beyond.
- [Upstream & Downstream (USP/DSP)](https://pan-biotech.com/upstream-downstream/): Guide to matched RUO/GMP media, buffers and Water for Injection across the full bioprocessing chain.

## Knowledge Hub & Case Studies

- [Knowledge Hub](https://pan-biotech.com/knowledge-hub/): Central resource portal — anonymised case studies (CS-01 to CS-06), In-Depth Industry Editions (D01, D02, A02), technical papers (TP-01 to TP-04), WFI Beyond, guides, press and podcast.
- [Case Studies](https://pan-biotech.com/case-studies/): Index of all anonymised customer case studies.
- [CS-01 — ~50,000 L of GMP supply in under five weeks](https://pan-biotech.com/gmp-media-supply-case-study/): Vaccine manufacturer; quote in 3 days, first delivery within two weeks of production start, ~50,000 L delivered in under five weeks.
- [CS-02 — A two-year OEM bridge, delivered under pressure](https://pan-biotech.com/a-two-year-oem-bridge-delivered-under-pressure/): After a regulatory shutdown of a global supplier's US site, PAN-Biotech scaled from ~7 to ~25 products and supplied ~150,000 L / ~300,000 bottles over two years (RUO & FFM) with no rejections recorded; production-ready in 40 days.
- [CS-03 — A private-label GMP line for Europe](https://pan-biotech.com/a-private-label-gmp-line-for-europe/): A global, Japan-headquartered company launched a private-label GMP product line for European customers without building a plant; PAN-Celltech as CMO/CDMO with EU Annex 1 process development, custom single-use packaging and full QC/QA.
- [CS-04 — Securing supply after a supplier discontinuation](https://pan-biotech.com/securing-supply-after-a-supplier-discontinuation/): An incumbent supplier discontinued an RUO / for-further-manufacturing product; PAN-Biotech took it over end-to-end under PAN Complete, including FDA product registration, sourcing, validated production, QA/QC and logistics.
- [CS-05 — From in-house buffer prep to a qualified GMP supply partner](https://pan-biotech.com/from-in-house-buffer-prep-to-a-qualified-gmp-supply-partner/): A monoclonal-antibody developer moved from preparing its own buffers to an audited GMP source, starting with GMP-grade DPBS (CT-36500, DMF MF044371) and expanding across process buffers and Water for Injection.
- [CS-06 — WFI Beyond in 1 mL vials for clinical CAR-T manufacturing](https://pan-biotech.com/beyond-compendial-water-in-1-ml-vials-for-plasmid-dilution-in-clinical-car-t-cell-manufacturing/): A CAR-T cell therapy developer needed nuclease-free, ultra-low-endotoxin water to dilute a plasmid before electroporating human T cells (Phase 1); PAN-Celltech custom-filled WFI Beyond into 1 mL vials, from enquiry to release in about eight weeks.

## Company

- [Company](https://pan-biotech.com/company/): Corporate history and milestones from PAN-Biotech's 1988 founding through serum-free media innovation, international expansion and GMP manufacturing.
- [About Us](https://pan-biotech.com/about-us/): Company mission, strategic focus areas (cell & gene therapy, vaccines, mRNA, antibodies) and leadership under CEO Jens Hartmann.
- [Quality Assurance](https://pan-biotech.com/quality-assurance/): Quality management system — ISO 9001:2015 and ISO 13485 certification, GMP manufacture in an EU Annex 1 facility (an audit-proven capability, not a certification), FDA registration and Drug Master Files (DMF).
- [Sustainability](https://pan-biotech.com/sustainability/): Environmental framework built on three pillars — Recycle, Reduce, Replace.
- [Awards](https://pan-biotech.com/awards/): Industry awards and recognitions.
- [Press](https://pan-biotech.com/press/): Company news and press coverage.
- [Podcast](https://pan-biotech.com/podcast/): PAN-Biotech's podcast on biomanufacturing topics.
- [Contact Us](https://pan-biotech.com/contact-us/): Contact information for sales and technical inquiries.

## Products

- [Products](https://pan-biotech.com/products/): Full catalog overview of cell culture media, sera, buffers and reagents.
- [Expanded Portfolio](https://pan-biotech.com/expanded-portfolio/): Broader product range beyond core cell culture media.
- [GMP Grade Products](https://pan-biotech.com/gmp-grade-products/): GMP-grade products, manufactured in an EU Annex 1 facility, for cell & gene therapy, mRNA, vaccine and antibody manufacturing.
- [Customized Products](https://pan-biotech.com/customized-products/): Custom-formulated media, buffers and reagents to customer specification.
- [Serum](https://pan-biotech.com/serum/): Fetal bovine serum and other animal-derived sera for cell culture.
- [Serum-Free Solutions](https://pan-biotech.com/serum-free-solutions/): Serum-free and chemically defined media alternatives.
- [Specialized Media](https://pan-biotech.com/specialized-media/): Custom and application-specific cell culture media formulations.
- [Media](https://pan-biotech.com/media/): Standard cell culture media (e.g. Alpha MEM, DMEM).
- [Buffer](https://pan-biotech.com/buffer/): GMP process buffers for downstream biomanufacturing.
- [Cryopreservation Media](https://pan-biotech.com/cryopreservation-media/): Media for freezing and long-term storage of cells.
- [Biologicals](https://pan-biotech.com/biologicals/): Biological raw materials and components.
- Water products: see "Downstream & Water — product entry points" above.

## Manufacturing & Supply

- [From RUO to GMP](https://pan-biotech.com/from-ruo-to-gmp/): Three-tiered quality system (RUO, GMP-ready, GMP-grade) supporting therapeutic development from research through commercialization; GMP facility with ~1M L/year capacity and Class D-A cleanrooms.
- [CMO / CDMO / OEM](https://pan-biotech.com/cmo-cdmo-oem/): Contract manufacturing services — flexible batch sizes (1-1,000 L), GMP manufacture in an EU Annex 1 facility, and "PAN Complete" end-to-end services (raw materials, production, testing, labeling, packaging, logistics).
- [Customized Solutions — PAN Complete](https://pan-biotech.com/custom-solutions/): Custom GMP formulations, custom fills and end-to-end supply services.
- [Logistic Solutions](https://pan-biotech.com/logistic-solutions/): Supply chain and logistics capabilities.
- [Gateway to Europe](https://pan-biotech.com/gateway-to-europe/): Market-entry / supply partnership offering for non-EU manufacturers into Europe.
- [Research and Development](https://pan-biotech.com/research-and-development/): R&D capabilities and process development support.
- [Quality Test and Research Center](https://pan-biotech.com/quality-test-and-research-center/): In-house testing and quality research facility.
- [Custom GMP Project Enquiry](https://pan-biotech.com/custom-gmp-project-enquiry/): Request form for custom GMP manufacturing projects, specifications, Certificates of Analysis and DMF Letters of Authorization.

## Applications & Technology

- [Applications](https://pan-biotech.com/applications/): Overview of solutions across cell & gene therapy, vaccine production, mRNA technology and antibody manufacturing.
- [Cell and Gene Therapy](https://pan-biotech.com/cell-and-gene-therapy/): Culture media and custom solutions for cell and gene therapeutic development.
- [mRNA Technology](https://pan-biotech.com/mrna-technology/): Reagents and process development for mRNA-based therapeutics.
- [Vaccine Production](https://pan-biotech.com/vaccine-production/): Viral culture media and process optimization for vaccine manufacturing.
- [Monoclonal Antibody Manufacturing](https://pan-biotech.com/monoclonal-antibody-manufacturing/): Media, buffers and process support for antibody production.

## Careers

- [Career](https://pan-biotech.com/career/): Open positions across production, lab, filling/preparation and sales.

## Events

- [CPHI Milan 2026](https://pan-biotech.com/event/cphi-milan-2026/) (6 October 2026)
- [Medica 2026](https://pan-biotech.com/event/medica-2026/) (16 November 2026)
- [analytica China 2026](https://pan-biotech.com/event/analytica-china-2026/) (16 November 2026)

## FAQ & Ordering

- [FAQ](https://pan-biotech.com/faq/): Frequently asked questions, including cell culture flask collection and PET recycling procedures.
- [Shop](https://shop.pan-biotech.de/en/): Online ordering portal for PAN-Biotech products.

## Legal

- [Terms and Conditions](https://pan-biotech.com/gtc/): General terms and conditions.
- [Privacy Policy](https://pan-biotech.com/privacy-policy-2/): Data privacy policy.
- [Imprint](https://pan-biotech.com/imprint/): Legal company registration details.

## Optional

- [Full sitemap](https://pan-biotech.com/sitemap_index.xml): Complete index of all site content, including individual product SKU pages and additional job/event listings.